Rapid NSCLC Biomarker Test already demonstrated its significant impact and clinical benefits as part of a lung cancer clinical study.

PD-L1 expression measured by immunohistochemistry helps identify non-small cell lung cancer (NSCLC) patients that may respond to anti-PD-1/PD-L1 immunotherapies.

The inhibitors work by aiming two DNA repair systems at the same time, killing cancer cells while evading the healthy cells.